Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXSFree Report) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock.

Separately, LADENBURG THALM/SH SH raised Ayala Pharmaceuticals from a neutral rating to a buy rating in a research note on Tuesday, May 30th.

Get Our Latest Research Report on ADXS

Ayala Pharmaceuticals Stock Performance

Ayala Pharmaceuticals stock opened at $1.00 on Wednesday. The company has a market capitalization of $1.82 million, a PE ratio of -0.11 and a beta of 2.34. Ayala Pharmaceuticals has a fifty-two week low of $0.65 and a fifty-two week high of $3.75. The firm has a 50 day moving average price of $1.09 and a 200 day moving average price of $1.02.

Ayala Pharmaceuticals Company Profile

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers.

Recommended Stories

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.